A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : SVR12

Search Conditions:
Search Keyword : SVR12
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: SVR12
Appearance Frequency: 516 time(s)
Long forms: 24

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
sustained virologic response at 12 weeks
(458 times)
Gastroenterology
(210 times)
HCV (321 times)
RBV (80 times)
DAAs (65 times)
0 [Real data oviral hepatitis Ctherapy in the Czech Republic].
SVR at 12 weeks after treatment
(24 times)
Gastroenterology
(15 times)
SVR (21 times)
HCV (18 times)
DAA (5 times)
2014 SVR12 is higher than SVR24 in treatment-naive hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.
SVR at 12 weeks
(7 times)
Liver Diseases
(1 time)
SVR (6 times)
HCV (5 times)
CHC (3 times)
2015 Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.
sustained virologic response (HCV RNA <25 IU/mL) 12weeks post-treatment
(2 times)
Gastroenterology
(1 time)
HCV (1 time)
RBV (1 time)
SOF (1 time)
2018 Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).
Sustained virological response assessed 12 weeks following cessation of treatment
(2 times)
DAAs (2 times)
GT1 (2 times)
HCV (2 times)
2019 Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials.
SVR (HCV RNA <25IU/ml) 12weeks post-treatment
(2 times)
Gastroenterology
(2 times)
DAA (1 time)
HCV (1 time)
SVR (1 time)
2016 Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
SVR 12 weeks after discontinuation of therapy
(2 times)
Gastroenterology
(2 times)
AE (2 times)
HCV (2 times)
PEG-IFN (2 times)
2015 Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
SVR 12 weeks after treatment completion
(2 times)
Gastroenterology
(1 time)
SVR (2 times)
ASV (1 time)
DCV (1 time)
2015 Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.
SVR at post-treatment week 12
(2 times)
Gastroenterology
(1 time)
SVR (2 times)
AEs (1 time)
CI (1 time)
2018 Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
10  serum HCV RNA levels 12 weeks after treatment end
(1 time)
Medicine
(1 time)
GT (1 time)
HCV (1 time)
SMV (1 time)
2018 Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study.
11  serum HCV-RNA 12weeks after the end of treatment
(1 time)
Medicine
(1 time)
--- 2019 Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study.
12  serum HCV-RNA at 12weeks after treatment completion
(1 time)
Gastroenterology
(1 time)
DAAs (1 time)
IFN (1 time)
PwH (1 time)
2020 High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
13  Sustained viral response after 12weeks of end of treatment
(1 time)
Liver Diseases
(1 time)
DCV (1 time)
RBV (1 time)
SOF (1 time)
2018 Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
14  sustained viral response by the 12th week of treatment
(1 time)
Geriatrics
(1 time)
DAAs (1 time)
HCC (1 time)
2017 The use of direct-acting antivirals in the treatment of elderly patients with hepatitis C Virus infection.
15  sustained virological response 12 weeks after completion of glecaprevir-pibrentasvir therapy
(1 time)
HCV (1 time)
NAT (1 time)
2019 Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study.
16  Sustained virological response was assessed at week 12
(1 time)
Gastroenterology
(1 time)
BOC (1 time)
DDIs (1 time)
HCV (1 time)
2015 Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence.
17  SVR (serum HCV <25 copies/mL) 12 weeks
(1 time)
Medicine
(1 time)
ARTs (1 time)
HCV (1 time)
HIV (1 time)
2014 Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.
18  SVR 12 weeks after therapy
(1 time)
Gastroenterology
(1 time)
HCV (1 time)
SVR (1 time)
2018 Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection.
19  SVR at 12 weeks after cessation of study treatment
(1 time)
Gastroenterology
(1 time)
CI (1 time)
HCV (1 time)
RBV (1 time)
2015 Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.
20  SVR at 12 wk after the treatment
(1 time)
Medicine
(1 time)
AEs (1 time)
HCV (1 time)
SOF/RBV (1 time)
2019 Sofosbuvir/Ribavirin therapy for patients experiencing failure of ombitasvir/paritaprevir/ritonavir + ribavirin therapy: Two cases report and review of literature.
21  SVR at follow-up Week 12
(1 time)
Gastroenterology
(1 time)
HCV (1 time)
NS5A (1 time)
SVR (1 time)
2018 Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens.
22  SVR at week 12 after EOT
(1 time)
Transplantation
(1 time)
AST (1 time)
DAA (1 time)
EOT (1 time)
2020 Long-Term Follow-up of Liver Transplant Recipients Treated With Direct-Acting Antiviral Agents for Hepatitis C Recurrence After Transplantation.
23  SVR rate at 12 weeks after completion of therapy
(1 time)
Gastroenterology
(1 time)
HCV (1 time)
ITT (1 time)
LT (1 time)
2016 Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
24  SVRs at week 12
(1 time)
Gastroenterology
(1 time)
DAA (1 time)
HCV (1 time)
HCV Ag (1 time)
2016 Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection.